How to Manage Drug Master File (DMF) Compliance in ANDA Submissions

Introduction: What is a Drug Master File (DMF)?

A Drug Master File (DMF) is a confidential submission to the U.S. Food and Drug Administration (FDA) that provides detailed information about the manufacturing, processing, packaging, and storing of a drug substance or drug product. In the context of Abbreviated New Drug Applications (ANDAs), DMFs—particularly Type II (for drug substances)—play a pivotal role in enabling generic drug applicants to cross-reference critical data held by an Active Pharmaceutical Ingredient (API) manufacturer.

Since the ANDA holder may not manufacture the API, the DMF allows the FDA to evaluate the safety, quality, and consistency of the API without disclosing proprietary information to the applicant. This mechanism facilitates generic drug development while protecting trade secrets.

Types of DMFs Relevant to ANDA Filings

Although five DMF types exist, only a few are directly relevant to ANDA submissions:

• Type II: Drug Substance, Drug Substance Intermediate, and Material Used in Their Preparation
• Type III: Packaging Materials (rarely used)
• Type IV: Excipients, Colorants, Flavors, Essence
• Type V: FDA-accepted reference information not included in the above

For most ANDAs, the critical component is the Type II DMF, which provides the detailed chemistry, manufacturing, and controls (CMC) information for the API.

Submission Process, LOA, and Regulatory Expectations

Letter of Authorization (LOA)

To reference a DMF in an ANDA, the DMF holder must provide a Letter of Authorization (LOA). This is a formal letter that permits the FDA to review the DMF on behalf of the ANDA applicant.

The LOA must include:

• DMF number and type (e.g., Type II)
• DMF holder name and address
• Specific drug product(s) or substance(s) authorized
• Submission date and referencing application (e.g., ANDA 212345)

The LOA should be submitted both by the ANDA applicant (in Module 1.4.3) and the DMF holder directly to the FDA.

DMF Format and Submission

Since May 2018, all DMFs submitted to the FDA must comply with electronic Common Technical Document (eCTD) format. DMFs not in eCTD format will be rejected.

A Type II DMF typically contains:

• Open (Applicant’s Part): General manufacturing flow chart, specifications, analytical methods, stability
• Closed (Restricted Part): Detailed manufacturing process, proprietary intermediates, control strategies

Both sections must be up-to-date and consistent with ICH guidelines (Q7, Q8, Q9, Q10).

GDUFA User Fee for DMF

Under the Generic Drug User Fee Amendments (GDUFA), a one-time DMF fee is required. The fee is paid by the DMF holder when the DMF is first referenced in a generic drug application.

The FDA maintains a DMF listing on its website. A DMF is deemed available for reference only after the fee is paid and completeness assessment is passed.

FDA Completeness Assessment and Deficiency Letters

After the DMF is first referenced, the FDA conducts a completeness assessment within 60 days. This is not a full scientific review, but a check for:

• eCTD structure
• Required content (specifications, stability, methods)
• Administrative compliance

If deficiencies are identified, the FDA issues a DMF Deficiency Letter to the DMF holder—not the ANDA applicant. It is the DMF holder’s responsibility to respond.

Role of DMF in ANDA Lifecycle

The ANDA relies on the DMF throughout its lifecycle. The DMF holder must:

• Submit annual updates to the FDA
• Notify ANDA holders of significant changes
• Maintain up-to-date contact information
• Facilitate responses during ANDA review

Failure to maintain the DMF can result in approval delays or withdrawal of authorization.

DMF and Facility Inspections

Facilities listed in the DMF (e.g., API manufacturing sites) may be subject to FDA inspections. The agency verifies:

• GMP compliance (ICH Q7)
• Consistency with submitted data
• Adequacy of documentation and controls

Findings may result in Form 483s or Warning Letters, impacting the linked ANDA approval timeline.

Case Example: DMF Deficiency Impact

A generic oncology drug ANDA was delayed due to unresolved DMF deficiencies, including lack of validation for an impurity method and missing retest period justification. The DMF holder failed to respond on time, triggering a CRL to the ANDA sponsor.

This case illustrates the importance of DMF holder vigilance, communication, and timely updates.

CEP vs DMF: For EU vs U.S. Filings

In Europe, the equivalent of a DMF is a Certificate of Suitability (CEP) issued by the EDQM. While a CEP is acceptable for EMA filings, it cannot be used in place of a U.S. DMF for ANDA submissions.

Sponsors must ensure that their API source holds a valid U.S. DMF in good standing, even if a CEP is available.

Conclusion: DMF Compliance is a Shared Responsibility

For ANDA applicants, selecting an API source with a compliant, up-to-date DMF is a critical decision. Sponsors should:

• Verify that the DMF is in eCTD format and listed
• Ensure the LOA is submitted correctly
• Monitor DMF holder’s regulatory performance and communication
• Anticipate inspection outcomes and facility readiness

By proactively managing DMF-related risks, applicants can prevent approval delays and ensure a smoother path through the ANDA review process.